Format

Send to

Choose Destination
Biomed Rep. 2014 Nov;2(6):915-917. Epub 2014 Sep 10.

Cathepsin K in treatment monitoring following intravenous zoledronic acid.

Author information

1
Department of Trauma Surgery, Otto von Guericke University, D-39120 Magdeburg, Germany.
2
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, D-39120 Magdeburg, Germany ; Medical Laboratory for Clinical Chemistry, Microbiology and Infectious Diseases, Department Molecular Genetics, Otto von Guericke University, D-39124 Magdeburg, Germany.
3
Department of Nephrology, Hypertension, Endocrinology and Metabolic Diseases, Otto von Guericke University, D-39120 Magdeburg, Germany.
4
Department of Biometry and Medical Informatics, Otto von Guericke University, D-39120 Magdeburg, Germany.

Abstract

Cathepsin K (CatK) is mainly expressed by osteoclasts and plays an important role in bone resorption. As CatK is expressed and secreted by osteoclasts during active bone resorption, it may be a useful and specific biochemical marker of osteoclastic activity. Therefore, CatK serum levels were studied for monitoring the treatment of females with postmenopausal osteoporosis by zoledronic acid. The serum CatK levels were determined in nine postmenopausal females before and after 3, 6 and 12 months of treatment. The levels were significantly reduced after 3 and 6 months (P<0.05), whereas they returned to baseline after 1 year. Taken together, the serum level of CatK may be suitable for monitoring anti-osteoporotic therapy in association with treatment response.

KEYWORDS:

bisphosphonat; bone density measurement; cathepsin K; compliance; osteoporosis

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center